Fulgent Genetics (FLGT) Enterprise Value (2015 - 2026)

Fulgent Genetics has reported Enterprise Value for 12 years, with the latest figure at -$262.7 million in Q2 2026.

• Quarterly Enterprise Value rose 11.82% year-over-year to -$262.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$262.7 million (up 11.82% YoY) and the FY2025 annual result came in at -$341.4 million, down 30.2% from the prior year.
• Enterprise Value improved to -$262.7 million in Q2 2026 per FLGT's latest filing, from -$282.0 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$216.6 million in Q3 2024 and troughed at -$578.3 million in Q1 2022.
• A 5-year average of -$389.8 million and a median of -$361.1 million in 2025 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value jumped 53.38% in 2024, then tumbled 75.86% in 2025.
• Over 5 years, Enterprise Value stood at -$523.0 million in 2022, then climbed by 18.37% to -$427.0 million in 2023, then soared by 38.6% to -$262.2 million in 2024, then plunged by 30.2% to -$341.4 million in 2025, then climbed by 23.05% to -$262.7 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$262.7 million, -$282.0 million, and -$341.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.